What Does IDEXX Laboratories’ Debt Look Like?
Over the past three months, shares of IDEXX Laboratories Inc. (NASDAQ:IDXX) increased by 11.84%. Before having a look…
JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $550
JP Morgan analyst Chris Schott maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $525 to $550.
Atlantic Equities Maintains Overweight on IDEXX Laboratories, Raises Price Target to $600
Atlantic Equities analyst Steve Chesney maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $470 to $600.
IDEXX Laboratories Forecast 2023 EPS Of $9.27-$9.75, YoY Growth Of 16%-21% As Reported And 19%-26% On Comparable Basis, Versus Estimate Of $9.5
The company expects 2023 revenue of $3.59-$3.69 billion, reflecting reported growth of 6.5% - 9.5% and organic growth of 7% - 10%, compared to the consensus of $3.62 billion.
Goldman Sachs Maintains Buy on IDEXX Laboratories, Raises Price Target to $530
Goldman Sachs analyst Nathan Rich maintains IDEXX Laboratories (NASDAQ:IDXX) with a Buy and raises the price target from $465 to $530.
Morgan Stanley Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $543
Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $573 to $543.
Gartner, Sony, Uber And Other Big Gainers From Tuesday
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.
Here’s How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 12.17% on an annualized basis producing an average annual return of 22.65%. Currently, IDEXX Laboratories has a market capitalization of $30.10 billion.
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
IDEXX Laboratories (NASDAQ: IDXX) suffers from currency fluctuations along with high dependence on third-party distributors. The stock carries a Zacks Rank #4 (Sell).
Morgan Stanley Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $573
Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $603 to $573.